Neoton (Phosphocreatine Sodium)

Phosphocreatine sodium provides an external source of phosphocreatine, which donates phosphate groups to ADP via the creatine kinase system. This rapid regeneration of ATP supports myocardial energy metabolism, especially during periods of reduced oxygen supply, helping to maintain contractile function.

The specific dose of Neoton is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Healthcare professionals set the infusion rate and total amount according to established protocols and individual therapeutic needs.

Safety data for phosphocreatine sodium in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Neoton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Neoton delivers phosphocreatine directly, targeting rapid ATP regeneration, whereas many other cardioprotective drugs act through vasodilation, beta‑blockade, or metabolic modulation. This direct energy‑support mechanism can be advantageous in acute ischemic settings, but clinical choice depends on patient profile and therapeutic goals.

Neoton must be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the solution. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required for administration.

Neoton is administered intravenously as a sterile solution for injection. The infusion is typically given over a controlled period under medical supervision, with vital signs monitored throughout the procedure to detect any hemodynamic changes.

Serious risks include severe hypotension, cardiac arrhythmias, anaphylactic reactions, hyperkalemia, and potential worsening of myocardial infarction symptoms. Immediate medical attention is required if any of these events occur during or after infusion.

Neoton is contraindicated in patients with known hypersensitivity to phosphocreatine sodium or any excipients in the formulation, and in those with uncontrolled cardiac arrhythmias or severe hemodynamic instability. Clinicians should evaluate each patient’s medical history before prescribing.